# Xuandai Nguyen

> Xuandai Nguyen, Ph.D., MBA, is Vice President, Head of Global Program Strategy and Chief of Staff to the CEO at Beacon Therapeutics, an ophthalmic gene therapy company working to restore sight in people with inherited and prevalent retinal diseases. A scientist-turned-strategist, Nguyen has spent more than two decades moving medicines from bench to market, with senior roles at Genentech, Forma Therapeutics and ACELYRIN spanning immunology, ophthalmology, respiratory and sickle cell disease. Trilingual and Berkeley- and Cornell-trained, Nguyen sits at the intersection of hard science and commercial strategy, translating complicated biology into the plans that decide which therapies reach patients.

- **Role:** Vice President, Head of Global Program Strategy and Chief of Staff to the CEO at Beacon Therapeutics
- **Organizations:** Beacon Therapeutics, ACELYRIN, Forma Therapeutics, Genentech, Boehringer Ingelheim, Alpine Consulting, Stanford University
- **Nationality:** American
- **Education:** B.A., University of California, Berkeley, MBA, Cornell University, Johnson Graduate School of Management, Postdoctoral Fellow, Stanford University
- **Known for:** Rose from academic scientist to VP-level biotech executive over a 20+ year career, Led global commercial strategy and marketing for a rare-disease (sickle cell) program at Forma Therapeutics, Held senior pipeline and portfolio strategy roles at Genentech spanning immunology and ophthalmology

## Career timeline

- **1999-2002** — Postdoctoral Fellow at Stanford University
- **2000s-2010s** — Senior leadership roles at Genentech across immunology, ophthalmology and respiratory portfolios
- **2020-2022** — VP, Global Head of Commercial Strategy and Marketing at Forma Therapeutics
- **2023-2025** — VP of Commercial Strategy and New Product Planning at ACELYRIN
- **2025** — VP, Head of Global Program Strategy and Chief of Staff to the CEO at Beacon Therapeutics

## Achievements

- Rose from academic scientist to VP-level biotech executive over a 20+ year career
- Led global commercial strategy and marketing for a rare-disease (sickle cell) program at Forma Therapeutics
- Held senior pipeline and portfolio strategy roles at Genentech spanning immunology and ophthalmology
- Holds both a Ph.D. and an MBA, bridging deep science and commercial strategy
- Serves in the dual role of program strategy leader and Chief of Staff to the CEO at Beacon Therapeutics

## Latest updates

- **2026-01** — Serving as VP, Head of Global Program Strategy and Chief of Staff to the CEO at Beacon Therapeutics, whose Series C financing reportedly reached $75M in a recent round.

## Links

- Website: https://beacontx.com
- LinkedIn: http://www.linkedin.com/in/xuandai-nguyen

---

Profile page: https://yespress.io/xuandai-nguyen
Published by YesPress — https://yespress.io
Last updated: 2026-07-07